KVA K V Pharma CL A

Glancy Binkow & Goldberg LLP announces that all persons or entities who purchased the securities of K-V Pharmaceutical Company (“K-V Pharmaceutical” or the “Company”) (NYSE:KV-A) (NYSE:KV-B) between February 14, 2011 and April 4, 2011, inclusive (the “Class Period”), have until December 19, 2011 to file a motion with the Court to be appointed as Lead Plaintiff. The securities fraud class action lawsuit was filed in the United States District Court for the Eastern District of Missouri.

A copy of the Complaint is available from the court or from Glancy Binkow & Goldberg LLP. Please contact us by phone to discuss this action or to obtain a copy of the Complaint at (310) 201-9150 or Toll Free at (888) 773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.

The Complaint charges K-V Pharmaceutical and certain of the Company’s executive officers with violations of federal securities laws. K-V Pharmaceutical is a specialty pharmaceutical company engaged in the acquisition, development, manufacture and marketing of branded and generic/non-branded prescription pharmaceutical products in the United States, primarily focusing on women’s healthcare. The Complaint alleges that during the Class Period defendants issued false and/or misleading statements concerning the Company’s business and financial prospects. Specifically, the Complaint alleges that defendants misrepresented that the Food and Drug Administration (FDA) had granted K-V Pharmaceutical the exclusive distribution rights over “Makena,” a drug used to prevent miscarriages, and that the FDA would enforce those rights by preventing K-V Pharmaceutical’s competitors from distributing generic formulations of the drug. The Complaint further alleges that defendants failed to disclose that the drug’s $1,500 price actually would reduce the availability of Makena to low-income and other at-risk groups.

Any person or group who suffered a loss as a result of purchasing K-V Pharmaceutical securities between February 14, 2011 and April 4, 2011, may ask the Court to be appointed as Lead Plaintiff, but must file a motion no later than the December 19, 2011 deadline. To be a member of the class you need not take action at this time; you may retain counsel of your choice or take no action and remain an absent class member. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1801 Avenue of the Stars, Suite 311, Los Angeles, California 90067, by telephone at (310) 201-9150, Toll Free at (888) 773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

K V Pharma CL A (NYSE:KVA)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024

K V Pharma CL A (NYSE:KVA)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024